Company news

Exelixis, Inc. news in 2026

Exelixis, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

November 3, 2026

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

October 29, 2026

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

October 15, 2026

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

August 31, 2026

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 5, 2026

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

July 22, 2026

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

June 21, 2026

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

May 29, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

May 27, 2026

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

May 21, 2026

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

May 18, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

May 7, 2026

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 4, 2026

Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026

April 21, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March

February 24, 2026

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

February 10, 2026

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

February 1, 2026

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

January 27, 2026

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

January 10, 2026

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

January 6, 2026

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

January 5, 2026

Calls in 2026

Decks in 2026